Clinical Trial

Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2025 (before its estimated August 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
"HCC is a major challenge due to greater recurrence rates and variable treatment responses. TACE is widely used, but its success relies on accurate follow-up imaging. CT Triphasic Liver Imaging plays a vital role in assessing treatment response, guiding clinical decisions, and improving patient outcomes. The purpose of this study is to investigate the relationship between response of treatment, gender, age, and the cause of HCC. The purpose of the study is to evaluate how well TACE (trans-arterial chemoembolization) works for patients with HCC.
Trial Details
NCT Number NCT07048665
Lead Sponsor Superior University
Conditions Hepatocellular Carcinoma
Enrollment 60 participants
Start Date 2025-03-17
Primary Completion 2025-08-30 (estimated)
Study Completion 2026-02-28 (estimated)
Updated on ClinicalTrials.gov 2025-07-02